The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TRIB | +42.7% | -93.82% | -42.69% | -98% |
| S&P | +15.66% | +86.6% | +13.29% | +1,562% |
Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. It operates through the Americas and Rest of World geographical segments. The company was founded by Ronan O'Caoimh and Denis R. Burger in June 1992 and is headquartered in Bray, Ireland.
The surprising withdrawal of an application for approval at the FDA is sending shares reeling.
Get the lowdown on the big news and what it means for your portfolio.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $10.97M | -30.8% |
| Gross Profit | $4.33M | -21.6% |
| Gross Margin | 39.45% | 4.6% |
| Market Cap | $12.08M | -25.8% |
| Market Cap / Employee | $30.13K | 0.0% |
| Employees | 401 | 5.5% |
| Net Income | -$6,042.19K | 10.6% |
| EBITDA | -$2,375.56K | -55.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.55M | -70.9% |
| Accounts Receivable | $10.89M | -37.7% |
| Inventory | 20.1 | -12.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $110.05M | 21.0% |
| Short Term Debt | $2.51M | 6.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -36.98% | -10.1% |
| Return On Invested Capital | -40.29% | -4.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1,708.29K | 45.8% |
| Operating Free Cash Flow | -$1,670.59K | 45.8% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.29 | -0.38 | -0.25 | -0.34 | -51.78% |
| Price to Sales | 0.19 | 0.19 | 0.19 | 0.24 | -28.65% |
| Price to Tangible Book Value | -0.12 | -0.14 | -0.09 | -0.14 | -47.32% |
| Enterprise Value to EBITDA | -63.11 | -23.90 | -27.93 | -51.83 | -26.84% |
| Total Debt | $93.72M | $100.76M | $107.97M | $112.56M | 20.60% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
